The FDA met with OpenAI to discuss how the agency could use AI tools for a project called cderGPT, which may stand for the Center for Drug Evaluation, according to a report from Wired. This week, FDA Commissioner Marty Makary brought up goals to eventually shorten the drug approval process with AI.